TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
EP0647449A1
(de)
*
|
1993-06-24 |
1995-04-12 |
Takeda Chemical Industries, Ltd. |
Zubereitung, die anhaltend eine Anti-Endothelin-Substanz freisetz
|
US6087324A
(en)
*
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
DE4342091A1
(de)
*
|
1993-12-09 |
1995-06-14 |
Asta Medica Ag |
Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
|
AU4459196A
(en)
*
|
1995-01-23 |
1996-08-14 |
Takeda Chemical Industries Ltd. |
Sustained-release preparation and use
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
TW448055B
(en)
*
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
US6143037A
(en)
*
|
1996-06-12 |
2000-11-07 |
The Regents Of The University Of Michigan |
Compositions and methods for coating medical devices
|
US5932547A
(en)
*
|
1996-07-03 |
1999-08-03 |
Alza Corporation |
Non-aqueous polar aprotic peptide formulations
|
US5916582A
(en)
*
|
1996-07-03 |
1999-06-29 |
Alza Corporation |
Aqueous formulations of peptides
|
US5981489A
(en)
*
|
1996-07-18 |
1999-11-09 |
Alza Corporation |
Non-aqueous protic peptide formulations
|
EP0839525B1
(de)
*
|
1996-10-31 |
2004-08-04 |
Takeda Chemical Industries, Ltd. |
Zubereitung mit verzögerter Freisetzung
|
US5968895A
(en)
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6126919A
(en)
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
US6030975A
(en)
*
|
1997-03-14 |
2000-02-29 |
Basf Aktiengesellschaft |
Carboxylic acid derivatives, their preparation and use in treating cancer
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
EP1158014B1
(de)
*
|
1998-12-15 |
2005-02-16 |
Takeda Pharmaceutical Company Limited |
Verfahren zur Herstellung biologisch-abbaubarer Polyester
|
JP2002537415A
(ja)
*
|
1999-02-19 |
2002-11-05 |
バイオサルフ アーゲー |
マイクロカプセルの製造のための生物分解性複合材料
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
AU2001264264A1
(en)
*
|
2000-06-14 |
2001-12-24 |
Takeda Chemical Industries Ltd. |
Sustained release compositions
|
US20030176360A1
(en)
|
2000-07-05 |
2003-09-18 |
Yasutaka Igari |
Medicinal preparations for treating sex hormone-dependent diseases
|
DK1310517T4
(da)
*
|
2000-08-07 |
2011-01-17 |
Wako Pure Chem Ind Ltd |
Mælkesyrepolymer og fremgangsmåde til fremstilling af denne
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
WO2002058672A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Microparticles of biodegradable polymer encapsulating a biologically active substance
|
WO2002058671A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Burst free pharmaceutical microparticules
|
CA2451187C
(en)
*
|
2001-06-22 |
2012-08-14 |
Southern Biosystems, Inc. |
Zero-order prolonged release coaxial implants
|
TWI225416B
(en)
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
EP1443907A1
(de)
|
2001-11-12 |
2004-08-11 |
Alkermes Controlled Therapeutics, Inc. |
Biokompatible polymer-mischungen und ihre verwendung
|
US7812044B2
(en)
|
2001-11-13 |
2010-10-12 |
Takeda Pharmaceutical Company Limited |
Anticancer agents
|
EP1476178A4
(de)
*
|
2002-02-14 |
2009-08-26 |
Bayer Pharmaceuticals Corp |
Formulierungsstrategien zur stabilisierung von peptiden in organischen lösungsmitteln und in getrockneten zuständen
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
ATE534652T1
(de)
|
2005-04-01 |
2011-12-15 |
Univ California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
US7342048B2
(en)
*
|
2005-04-28 |
2008-03-11 |
Nipro Corporation |
Bioabsorbable pharmaceutical formulation
|
CN101309688B
(zh)
*
|
2005-05-23 |
2016-06-22 |
自然选择国际公司 |
持续释放β-丙氨酸的组合物和方法
|
AR055346A1
(es)
*
|
2005-06-30 |
2007-08-22 |
Sod Conseils Rech Applic |
Composiciones farmaceuticas de glp -1
|
US8882747B2
(en)
*
|
2005-11-09 |
2014-11-11 |
The Invention Science Fund I, Llc |
Substance delivery system
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
US20080076812A1
(en)
*
|
2006-03-13 |
2008-03-27 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
EP1996162A2
(de)
*
|
2006-03-13 |
2008-12-03 |
Encysive Pharmaceuticals, Inc |
Verfahren und zusammensetzungen zur behandlung von diastolischer herzinsuffizienz
|
DK2383271T3
(da)
*
|
2006-03-13 |
2013-10-07 |
Kyorin Seiyaku Kk |
Aminoquinoloner som GSK-3-inhibitorer
|
US8323676B2
(en)
*
|
2008-06-30 |
2012-12-04 |
Abbott Cardiovascular Systems Inc. |
Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
|
US20090258028A1
(en)
*
|
2006-06-05 |
2009-10-15 |
Abbott Cardiovascular Systems Inc. |
Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
US8017237B2
(en)
|
2006-06-23 |
2011-09-13 |
Abbott Cardiovascular Systems, Inc. |
Nanoshells on polymers
|
ES2422864T3
(es)
|
2006-08-09 |
2013-09-16 |
Intarcia Therapeutics, Inc |
Sistemas de liberación osmótica y unidades de pistón
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
JP2010507585A
(ja)
|
2006-10-19 |
2010-03-11 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
置換インドール
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
JP5241507B2
(ja)
|
2006-11-30 |
2013-07-17 |
武田薬品工業株式会社 |
環状アミン化合物
|
EA016176B1
(ru)
*
|
2006-12-18 |
2012-02-28 |
Такеда Фармасьютикал Компани Лимитед |
Композиция с замедленным высвобождением и способ её получения
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
ATE525068T1
(de)
*
|
2007-02-28 |
2011-10-15 |
Conatus Pharmaceuticals Inc |
Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
|
US20080220104A1
(en)
*
|
2007-03-08 |
2008-09-11 |
Cappello John V |
Compositions for producing satiety
|
SI2125698T1
(sl)
|
2007-03-15 |
2016-12-30 |
Auspex Pharmaceuticals, Inc. |
Devterirani d9-venlafaksin
|
EP2139447A2
(de)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
|
WO2008133908A2
(en)
|
2007-04-23 |
2008-11-06 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
BRPI0814542A2
(pt)
*
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
ITSA20070024A1
(it)
*
|
2007-07-27 |
2009-01-28 |
Univ Degli Studi Salerno |
Processo continuo per la produzione di microsfere mediante liquidi espansi.
|
MX2010002667A
(es)
*
|
2007-09-11 |
2010-04-01 |
Activx Biosciences Inc |
Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
|
MX2010002662A
(es)
|
2007-09-12 |
2010-04-09 |
Activx Biosciences Inc |
Aminoquinolonas espirociclicas como inhibidores de gsk-3.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
MY161576A
(en)
|
2008-03-17 |
2017-04-28 |
Ambit Biosciences Corp |
Quinazoline derivatives as raf kinase modulators and methods of use thereof
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
NZ589469A
(en)
*
|
2008-05-20 |
2012-08-31 |
Cerenis Therapeutics Holding S A |
Niacin and NSAID combination for reducing niacin-induced flushing
|
US8765162B2
(en)
*
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
CN102177172A
(zh)
|
2008-07-02 |
2011-09-07 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
SG10201703039SA
(en)
*
|
2008-09-04 |
2017-05-30 |
Amylin Pharmaceuticals Llc |
Sustained release formulations using non-aqueous carriers
|
WO2010076329A1
(en)
|
2008-12-31 |
2010-07-08 |
Scynexis, Inc. |
Derivatives of cyclosporin a
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
SI2401267T1
(sl)
|
2009-02-27 |
2014-05-30 |
Ambit Biosciences Corporation |
Derivati kinazolina, ki modulirajo JAK-kinazo, in njihova uporaba v postopkih
|
EP2403860B1
(de)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene und phosphothiazole als hcv polymerase inhibitoren
|
WO2010105016A1
(en)
|
2009-03-11 |
2010-09-16 |
Ambit Biosciences Corp. |
Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
|
CN102421784B
(zh)
*
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
SG174527A1
(en)
|
2009-03-27 |
2011-11-28 |
Pathway Therapeutics Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
PE20120811A1
(es)
|
2009-04-22 |
2012-07-08 |
Axikin Pharmaceuticals Inc |
Antagonistas ccr3 arilsulfonamida
|
EP2421829B1
(de)
|
2009-04-22 |
2015-09-30 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituierte arylsulfonamide als ccr3-antagonisten
|
ES2664984T3
(es)
|
2009-04-22 |
2018-04-24 |
SMA Therapeutics, Inc. |
Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
|
US8911766B2
(en)
*
|
2009-06-26 |
2014-12-16 |
Abbott Cardiovascular Systems Inc. |
Drug delivery compositions including nanoshells for triggered drug release
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
HUE035519T2
(en)
|
2009-07-08 |
2018-05-02 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical composition
|
EP2467144A1
(de)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Kombination aus proteasehemmern und antihepatitismedikation zur behandlung von hepatitis
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
WO2011037623A1
(en)
|
2009-09-28 |
2011-03-31 |
Intarcia Therapeutics, Inc. |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
TW201120037A
(en)
*
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
MX2012006877A
(es)
|
2009-12-18 |
2012-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
JP2013516424A
(ja)
|
2009-12-30 |
2013-05-13 |
サイネクシス,インコーポレーテッド |
シクロスポリン類似体
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
UA115523C2
(uk)
|
2010-02-05 |
2017-11-27 |
Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" |
Тверді форми макроциклічних інгібіторів кінази
|
RS56232B1
(sr)
|
2010-02-11 |
2017-11-30 |
Celgene Corp |
Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
|
WO2011109345A1
(en)
|
2010-03-02 |
2011-09-09 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
AU2011227232B2
(en)
|
2010-03-17 |
2015-07-09 |
Axikin Pharmaceuticals Inc. |
Arylsulfonamide CCR3 antagonists
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
CN103153309A
(zh)
|
2010-06-01 |
2013-06-12 |
拜欧赛里克斯公司 |
使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
|
CN104926722A
(zh)
|
2010-06-01 |
2015-09-23 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
CN104860907A
(zh)
|
2010-06-07 |
2015-08-26 |
诺沃梅迪科斯有限公司 |
呋喃基化合物及其用途
|
US9295663B2
(en)
|
2010-07-14 |
2016-03-29 |
Abbott Cardiovascular Systems Inc. |
Drug coated balloon with in-situ formed drug containing microspheres
|
EP2595615A1
(de)
|
2010-07-19 |
2013-05-29 |
Summa Health System |
Vitamin c und chromfreies vitamin k sowie zusammensetzungen daraus zur behandlung von nfkb-induzierten leiden oder erkrankungen
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
CA2809994A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
EP2611793A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cyclochinazolinderivate und verwendungsverfahren dafür
|
EP2611812A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridin- und thienopyrimidinverbindungen sowie verfahren zu ihrer verwendung
|
EP2611792B1
(de)
|
2010-09-01 |
2017-02-01 |
Ambit Biosciences Corporation |
Hydrobromid salze einer pyrazolylaminoquinazolin
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
WO2012030944A2
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
MX2013002384A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Compuestos quinazolina y metodos para utilizarlos.
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
US20120088769A1
(en)
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環化合物及びその使用
|
AU2011338530B2
(en)
|
2010-12-06 |
2017-06-15 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
KR101411349B1
(ko)
*
|
2010-12-24 |
2014-06-25 |
주식회사 삼양바이오팜 |
생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
|
MX347708B
(es)
|
2011-01-10 |
2017-05-09 |
Infinity Pharmaceuticals Inc |
Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
SI2683384T1
(sl)
|
2011-03-11 |
2016-05-31 |
Celgene Corporation |
Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
|
BR112013024907A2
(pt)
|
2011-03-28 |
2016-12-20 |
Mei Pharma Inc |
composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
|
CA2831590A1
(en)
|
2011-03-28 |
2012-10-04 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
EP2691388A1
(de)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
JP2014514295A
(ja)
|
2011-03-31 |
2014-06-19 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
EP2751093A1
(de)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclische verbindungen und ihre verwendung
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
EP2755985B1
(de)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
MX368081B
(es)
|
2011-10-14 |
2019-09-19 |
Ambit Biosciences Corp |
Compuestos heterociclicos y uso de los mismos como moduladores del receptor de tirosina cinasas tipo iii.
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
AU2012355983A1
(en)
|
2011-12-21 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013138613A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013177219A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
D-amino acid compounds for liver disease
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
US9517210B2
(en)
|
2012-07-12 |
2016-12-13 |
Takeda Pharmaceutical Company Limited |
Method for producing microcapsule powder
|
ES2885769T3
(es)
|
2012-08-09 |
2021-12-15 |
Celgene Corp |
Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
|
EP2882441B1
(de)
|
2012-08-09 |
2020-04-29 |
Celgene Corporation |
Behandlung von immunbedingten entzündungserkrankungen
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
TW201414721A
(zh)
|
2012-09-07 |
2014-04-16 |
Axikin Pharmaceuticals Inc |
同位素濃化之芳磺醯胺ccr3拮抗劑
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
TR201809048T4
(tr)
|
2012-10-08 |
2018-07-23 |
Centre Nat Rech Scient |
Hcv enfeksiyonu için 2'-kloro nükleosit analogları.
|
EP2909223B1
(de)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinukleotidverbindungen für hcv-infektion
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
RS58023B2
(sr)
|
2012-11-01 |
2021-12-31 |
Infinity Pharmaceuticals Inc |
Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
CN104955801B
(zh)
|
2012-11-30 |
2017-10-31 |
诺沃梅迪科斯有限公司 |
取代的二芳基磺酰胺及其用途
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
EP2943188A1
(de)
|
2013-01-11 |
2015-11-18 |
Mayo Foundation for Medical Education and Research |
Vitamine c und k zur behandlung polyzystischer erkrankungen
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
US20160024051A1
(en)
|
2013-03-15 |
2016-01-28 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
EP3003309B1
(de)
|
2013-05-30 |
2020-09-09 |
Infinity Pharmaceuticals, Inc. |
Behandlung von krebs mit pi3-kinase-isoformmodulatoren
|
EP3004130B1
(de)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thionukleoside zur behandlung von hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
RU2016111675A
(ru)
|
2013-08-30 |
2017-10-04 |
Эмбит Байосайенсиз Корпорейшн |
Соединения биарилацетамида и способы их применения
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(de)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibitoren des hepatitis-c-virus
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
PE20160685A1
(es)
|
2013-10-04 |
2016-07-23 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
CN104587534A
(zh)
*
|
2013-10-31 |
2015-05-06 |
先健科技(深圳)有限公司 |
可吸收铁基合金支架
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
RU2016125213A
(ru)
|
2013-11-27 |
2017-12-29 |
АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Нуклеотиды для лечения рака печени
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
MX2016012021A
(es)
|
2014-03-19 |
2017-04-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
|
MX2016012097A
(es)
|
2014-03-20 |
2017-04-27 |
Capella Therapeutics Inc |
Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
|
KR102409739B1
(ko)
|
2014-03-20 |
2022-06-17 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 erbb 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
CA2944549A1
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxin useful for the treatment of pain
|
CN106456704A
(zh)
|
2014-04-16 |
2017-02-22 |
Veyx-药物有限公司 |
兽药组合物和其应用
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
ES2751652T3
(es)
|
2014-05-12 |
2020-04-01 |
Conatus Pharmaceuticals Inc |
Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
|
WO2015181624A2
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals, Inc |
Nucleoside derivatives for the treatment of cancer
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
MA40240B1
(fr)
|
2014-06-19 |
2019-03-29 |
Ariad Pharma Inc |
Composés hétéroaryle d'inhibition de la kinase
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
WO2016020901A1
(en)
|
2014-08-07 |
2016-02-11 |
Acerta Pharma B.V. |
Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
|
CA2960284A1
(en)
|
2014-09-12 |
2016-03-17 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
KR20210142781A
(ko)
|
2014-10-21 |
2021-11-25 |
다케다 야쿠힌 고교 가부시키가이샤 |
결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-{2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
|
WO2016065264A1
(en)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
TWI703133B
(zh)
|
2014-12-23 |
2020-09-01 |
美商艾克斯基製藥公司 |
3,5-二胺基吡唑激酶抑制劑
|
JP6856532B2
(ja)
|
2015-01-20 |
2021-04-07 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
エルゴリン化合物およびその使用
|
US9676776B2
(en)
|
2015-01-20 |
2017-06-13 |
Xoc Pharmaceuticals, Inc. |
Isoergoline compounds and uses thereof
|
EP3303361A1
(de)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nukleotide zur behandlung von krebs
|
CN113598842A
(zh)
|
2015-06-03 |
2021-11-05 |
因塔西亚制药公司 |
植入物放置和移除系统
|
MX2017017015A
(es)
|
2015-06-23 |
2018-02-26 |
Neurocrine Biosciences Inc |
Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
|
CN108371711A
(zh)
|
2015-08-17 |
2018-08-07 |
库拉肿瘤学公司 |
使用法尼基转移酶抑制剂治疗癌症患者的方法
|
CA3000708A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
CN115322188A
(zh)
|
2015-10-30 |
2022-11-11 |
纽罗克里生物科学有限公司 |
Valbenazine盐及其多晶形物
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
CN108925135A
(zh)
|
2015-12-23 |
2018-11-30 |
纽罗克里生物科学有限公司 |
制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
|
WO2017117478A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
ES2957477T3
(es)
|
2016-01-08 |
2024-01-19 |
Celgene Corp |
Compuestos antiproliferativos para usar en el tratamiento de leucemia
|
WO2017120415A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
JP6880037B2
(ja)
|
2016-01-08 |
2021-06-02 |
セルジーン コーポレイション |
がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
CN109476635B
(zh)
|
2016-04-29 |
2021-07-13 |
Fgh生物科技公司 |
用于治疗疾病的二取代吡唑类化合物
|
EP3458084B1
(de)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ES2932187T3
(es)
|
2016-09-07 |
2023-01-16 |
Fgh Biotech Inc |
Compuestos de pirazol disustituidos para el tratamiento de enfermedades
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
RS61745B1
(sr)
|
2016-11-03 |
2021-05-31 |
Kura Oncology Inc |
Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
|
WO2018089427A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
EP3548007A4
(de)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
Verfahren zur behandlung von krebs
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪(valbenazine)於治療精神分裂症或情感性精神分裂症之用途
|
EP3565580B1
(de)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
|
MX2019008853A
(es)
|
2017-01-27 |
2019-09-11 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
|
WO2018156609A1
(en)
|
2017-02-21 |
2018-08-30 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
WO2018183781A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US11279706B2
(en)
|
2017-03-29 |
2022-03-22 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
EP3624796A1
(de)
|
2017-05-19 |
2020-03-25 |
NFlection Therapeutics, Inc. |
Pyrrolopyridinanilinverbindungen zur behandlung von hauterkrankungen
|
DK3624795T3
(da)
|
2017-05-19 |
2022-05-23 |
Nflection Therapeutics Inc |
Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
|
CA3064274A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019032489A1
(en)
|
2017-08-07 |
2019-02-14 |
Kura Oncology, Inc. |
METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
|
MX2020002841A
(es)
|
2017-09-21 |
2020-07-22 |
Neurocrine Biosciences Inc |
Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
US20200230127A1
(en)
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
TW201929847A
(zh)
|
2018-01-10 |
2019-08-01 |
美商克拉治療有限責任公司 |
包含二羧酸之醫藥組合物及其治療應用
|
TWI823890B
(zh)
|
2018-01-10 |
2023-12-01 |
美商克拉治療有限責任公司 |
包含苯基磺醯胺之醫藥組合物及其治療應用
|
WO2019241555A1
(en)
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
CN112867491A
(zh)
|
2018-08-15 |
2021-05-28 |
纽罗克里生物科学有限公司 |
施用某些vmat2抑制剂的方法
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US20220002396A1
(en)
|
2018-11-01 |
2022-01-06 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
JP7406264B2
(ja)
|
2018-11-20 |
2023-12-27 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのシアノアリール-アニリン化合物
|
CA3120337A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
AU2019384064A1
(en)
|
2018-11-20 |
2021-06-10 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
AU2019383310A1
(en)
|
2018-11-20 |
2021-06-10 |
H. Lee Moffitt Cancer Center & Research Institute |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
EP3897638A1
(de)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Therapien für plattenepithelkarzinome
|
TW202045481A
(zh)
|
2019-02-06 |
2020-12-16 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3935042A1
(de)
|
2019-03-07 |
2022-01-12 |
Conatus Pharmaceuticals, Inc. |
Caspase-inhibitoren und verfahren zur verwendung davon
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2020254492A1
(en)
|
2019-03-29 |
2021-11-11 |
Kura Oncology, Inc. |
Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
US20220274921A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
BR112022000993A2
(pt)
|
2019-07-26 |
2022-06-07 |
Espervita Therapeutics Inc |
Ácidos mono- e dicarboxílicos de hidrocarboneto de cadeia longa funcionalizados úteis para a prevenção ou tratamento de doença
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
MX2022003166A
(es)
|
2019-09-16 |
2022-06-29 |
Dice Alpha Inc |
Moduladores de il-17a y usos de los mismos.
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
EP4037687A4
(de)
|
2019-10-01 |
2023-09-27 |
Molecular Skin Therapeutics, Inc. |
Benzoxazinon-verbindungen als duale klk5/7-inhibitoren
|
CA3179635A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
EP4168414A1
(de)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
|
IL300626A
(en)
|
2020-08-14 |
2023-04-01 |
Siteone Therapeutics Inc |
Ketone-free inhibitors of NAV1.7 for the treatment of pain
|
EP4284377A1
(de)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Verfahren zur behandlung von fibrotischen erkrankungen
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
CN117642396A
(zh)
|
2021-03-10 |
2024-03-01 |
戴斯分子Sv有限公司 |
αVβ6和αVβ1整联蛋白抑制剂及其用途
|
EP4326721A1
(de)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
|
EP4347568A1
(de)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryldiamid-ire1/xbp1s-aktivatoren
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023192817A1
(en)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
US20230348909A1
(en)
|
2022-03-30 |
2023-11-02 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|